Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Clinical trial NCT06223711 · RECRUITING

Trial details

NCT number: NCT06223711
Sponsor: Universität des Saarlandes
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Extensive-stage Small-cell Lung Cancer

Start date: 2023-10-06
Primary completion: 2027-03-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.